Plus Therapeutics Relocates Principal Executive Offices
Ticker: PSTV · Form: 8-K · Filed: Aug 13, 2025 · CIK: 1095981
| Field | Detail |
|---|---|
| Company | Plus Therapeutics, Inc. (PSTV) |
| Form Type | 8-K |
| Filed Date | Aug 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $2.5 million, $23,641,000, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, address-change
TL;DR
PLUS THERAPEUTICS moved HQ to Houston, TX. New address: 2710 Reed Rd, Ste 160.
AI Summary
On August 13, 2025, PLUS THERAPEUTICS, INC. filed an 8-K report. The filing indicates a change in the company's principal executive offices from Austin, TX to Houston, TX. The new address is 2710 Reed Road, Suite 160, Houston, Texas 77051.
Why It Matters
This relocation may signal operational changes or a strategic shift for Plus Therapeutics, potentially impacting its accessibility for investors and partners.
Risk Assessment
Risk Level: low — The filing reports a change of address for the principal executive offices, which is a routine administrative event with no immediate financial or operational implications.
Key Players & Entities
- PLUS THERAPEUTICS, INC. (company) — Registrant
- August 13, 2025 (date) — Date of Report
- 2710 Reed Road, Suite 160, Houston, Texas 77051 (location) — New Principal Executive Offices Address
- Austin, TX (location) — Former Principal Executive Offices Location
FAQ
What is the new address for PLUS THERAPEUTICS, INC.'s principal executive offices?
The new address is 2710 Reed Road, Suite 160, Houston, Texas 77051.
When was this change of address reported?
The change of address was reported on August 13, 2025.
What was the previous location of the principal executive offices?
The previous location was in Austin, Texas.
Is this a significant operational change for the company?
The filing itself does not indicate a significant operational change, only a change in the physical address of the principal executive offices.
Does the filing mention any reasons for the relocation?
No, the filing does not provide specific reasons for the relocation of the principal executive offices.
Filing Stats: 645 words · 3 min read · ~2 pages · Grade level 12.3 · Accepted 2025-08-13 06:04:43
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 PSTV The Nasdaq Capital Market Ind
- $2.5 million — ule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders' equity (the "Minimum S
- $23,641,000 — rted stockholders' equity (deficit) of ($23,641,000) in its Quarterly Report on Form 10-Q f
- $1.00 — e Company's common stock meet or exceed $1.00 per share for a minimum of 10 consecuti
Filing Documents
- d930191d8k.htm (8-K) — 23KB
- 0001193125-25-179382.txt ( ) — 134KB
- pstv-20250813.xsd (EX-101.SCH) — 3KB
- pstv-20250813_lab.xml (EX-101.LAB) — 18KB
- pstv-20250813_pre.xml (EX-101.PRE) — 11KB
- d930191d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 13, 2025 PLUS THERAPEUTICS, INC. By: /s/ Marc H. Hedrick, M.D. Marc H. Hedrick, M.D. President and Chief Executive Officer